Effect of BCR-ABL1 Transcript Type and Body Weight on Outcome in Chronic Myeloid Leukemia

被引：0

作者：

Abdulla, Mohammad Abdul-Jaber ^{[1
]}

Chandra, Prem ^{[2
]}

Elakiki, Susana ^{[1
]}

Aldapt, Mahmood B. ^{[3
]}

Sardar, Sundus ^{[4
]}

Chapra, Ammar ^{[4
]}

Nashwan, Abdulqadir Jeprel ^{[5
]}

Sorio, Claudio ^{[6
]}

Tomasello, Luisa ^{[7
]}

Boni, Christian ^{[6
]}

Yassin, Mohamed A. ^{[8
]}

机构：

[1] Hamad Med Corp, Doha, Qatar

[2] Hamad Med Corp, Med Res Ctr, Biostat Sect, Doha, Qatar

[3] Natl Ctr Canc Care & Res HMC, Doha, Qatar

[4] Hamad Med Corp, Dept Internal Med, Doha, Qatar

[5] Hamad Med Corp, Dept Nursing 4, Hazm Mebaireek Gen Hosp, Doha, Qatar

[6] Univ Verona, Verona, Italy

[7] Ohio State Univ, Columbus, OH 43210 USA

[8] Natl Ctr Canc Care & Res, Dept Hematol Oncol, Doha, Qatar

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-144654

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4611

引用

页数：6

共 50 条

[41] BCR gene breakpoint and type of BCR/ABL-transcript in children with chronic myeloid leukemia.
Suttorp, M
Viehmann, S
Claviez, A
Martiniak, Y
Harbott, J
BLOOD, 2005, 106 (11) : 295B - 296B
[42] Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line
Stephanie Dulucq
Gabriel Etienne
Stephane Morisset
Emilie Klein
Claudine Chollet
Fanny Robbesyn
Beatrice Turcq
Isabelle Tigaud
Sandrine Hayette
Franck E. Nicolini
François-Xavier Mahon
Annals of Hematology, 2019, 98 : 1159 - 1168
[43] Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line
Dulucq, Stephanie
Etienne, Gabriel
Morisset, Stephane
Klein, Emilie
Chollet, Claudine
Robbesyn, Fanny
Turcq, Beatrice
Tigaud, Isabelle
Hayette, Sandrine
Nicolini, Franck E.
Mahon, Francois-Xavier
ANNALS OF HEMATOLOGY, 2019, 98 (05) : 1159 - 1168
[44] Molecular Monitoring of Chronic Myeloid Leukemia International Standardization of BCR-ABL1 Quantitation
Zhen, ChaoJie
Wang, Y. Lynn
JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 556 - 564
[45] Assessment of BCR-ABL1 transcript levels at 3 months is the major determinant for outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Katalinic, D.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S100 - S100
[46] Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient
Zamecnikova, Adriana
Al Bahar, Soad
Pandita, Ramesh
HEMATOLOGY, 2012, 17 (06) : 321 - 324
[47] Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia
Langabeer, Stephen E.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (08) : 969 - 969
[48] Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia
Tang, Yanjing
Wei, Xiaoyuan
Chen, Jing
Du, Yunzhi
Chu, Huiling
Mao, Louise
Chen, Jun
Xu, Qing
Tang, Jingyan
Shen, Shuhong
Mao, Mao
LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2216 - 2218
[49] Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
Smith, Brittany M.
Brewer, Diana
Druker, Brian J.
Braun, Theodore P.
CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1707 - 1711
[50] Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
Langabeer, Stephen E.
McCarron, Sarah L.
Haslam, Karl
Preston, Lisa
CLINICAL LABORATORY, 2016, 62 (05) : 975 - 976

← 1 2 3 4 5 →